Jan 23, 2023
Mehdi Maghsoodnia is the CEO of 1health and is determined to bring advanced diagnostic medical tests to a broader audience to enable more patients to benefit from precision medicine advancements. Too often, patients are put on costly drugs that are not effective. Using data from advanced testing allows clinicians to diagnose conditions more accurately and to determine the best treatment approach.
Mehdi elaborates, "Where we focus is really more on how do we make these advanced diagnostic tests cheaper and faster, so we can introduce more accurate, clean data into that care pathway. You want to know very quickly, very accurately, all that you need to know about the specifics of the patient, the specifics of their genetics, and the specifics of the potential tumor type, interaction with drugs, and so on and so forth. Those are the types of information we are trying to deliver into the care decision pathway very quickly."
"That data set is building up very rapidly because we've been sequencing patients, and we've been tracking the impact of the drug on those patients. Now, those databases are coming to the clinical market. They're not there today everywhere, so unfortunately, you might get the best pharmacogenomic results in some of the advanced institutions in urban areas, like San Francisco and New York, but you don't get it everywhere."
"Part of our push on the pharmacogenomic side is to make sure that it's available and accessible by everybody. Health equity is a big issue right now. We are making sure that the test is not only affordable, but it's easy to order, and it's easy to include in the healthcare pathway for every patient at every point in the care system."
@ihealthio #1health #PrecisionMedicine #AdvancedDiagnostics #DiagnosticTesting #CancerDetection #Pharmacogenomic